Alopecia Areata: The Autoimmune Hair Loss That Doesn't Follow the Usual Rules

What Alopecia Areata Actually Is

Alopecia areata is a chronic autoimmune disease in which the body's immune system mistakenly attacks its own hair follicles, causing hair production to stop without destroying the follicle itself. This distinction is important: because the follicle survives, the potential for regrowth remains. The follicle is not dead - it is dormant under immune attack.

The condition affects roughly 2 percent of the global population at some point in their lifetime. It can begin at any age, though onset before age 30 is most common, and it affects men and women equally.

The hallmark presentation is a round or oval patch of complete hair loss on the scalp. The affected skin is smooth and normal in color. There is no scarring, and the skin in the affected areas appears normal or slightly reddened (Pratt et al., Nature Reviews Disease Primers). To the untrained eye, the skin looks entirely healthy - which is part of what makes this condition so disorienting for the people experiencing it.

The exclamation-mark hair: a key clinical sign

At the edge of an active alopecia areata patch, dermatologists often find what are called exclamation-mark hairs (also called exclamation-point hairs): short hair shafts that are wider at the tip than at the base. The inflammation at the follicle narrows the base of the hair before it breaks, creating the characteristic shape. Their presence under dermoscopy is a reliable sign of active disease.

Types and Presentations

Alopecia areata is not a single presentation. Dermatologists classify it by the extent and pattern of hair loss:

• Alopecia areata (patchy) - One or more round or oval patches on the scalp or other hair-bearing areas. The most common form. Patches may be isolated or multiple.
• Alopecia totalis - Complete loss of all scalp hair. Considered a more severe form; responds less predictably to treatment than limited patchy disease.
• Alopecia universalis - Complete loss of all body hair, including eyebrows, eyelashes, and body hair. The most extensive form.
• Ophiasis pattern - Hair loss in a band along the sides and back of the scalp (the hairline and nape). Linked to a poorer prognosis (Canadian Family Physician).
• Sisaipho pattern - The inverse of ophiasis: hair loss spares the sides while affecting the crown and top. Less common.

How It Differs from Other Hair Loss

One of the most common points of confusion in a salon setting is distinguishing alopecia areata from the other types of hair loss a client might present with. The patterns are fundamentally different, and the causes require completely different responses.

What Triggers the Immune Response

Alopecia areata is not caused by a single factor. Current evidence points to a combination of genetic predisposition and environmental or physiological triggers that can precipitate an episode in susceptible individuals.

Genetic predisposition

Multiple HLA gene variants - particularly HLA class II loci including HLA-DQB1 and HLA-DR - have been identified as significant risk factors in genome-wide association studies. These genes influence how the immune system distinguishes self from non-self. Having a first-degree relative with alopecia areata increases a person's risk, though the condition does not follow a simple hereditary pattern.

Associated autoimmune conditions

People with alopecia areata are more likely to have other autoimmune conditions, including thyroid disease (both hypothyroidism and Hashimoto's), vitiligo, atopic dermatitis, and psoriasis. This co-occurrence reflects shared immune pathways rather than one condition causing another.

Stress and environmental factors

Many people with new-onset alopecia areata report a recent stressful event, such as a loss, a surgery or strain at home or work, but stress has never been proven to cause the condition (Cleveland Clinic). Stress does not create the autoimmune predisposition - it may act as a precipitant in people who already carry that genetic risk. Other environmental factors have been proposed in the literature, though no specific external trigger is established as causal.

It is worth being clear about what stress does not do: it does not cause alopecia areata in people without the underlying predisposition. Stress more commonly produces a different, recoverable form of hair loss called telogen effluvium, which causes diffuse shedding rather than round patches. Understanding this distinction matters for anyone who has been told their alopecia areata is "just stress."

Diagnosis: What a Dermatologist Looks For

In most cases, a dermatologist can diagnose alopecia areata clinically - by examination alone. The round, smooth, well-defined patch with a normal-appearing scalp surface is distinctive enough that additional testing is often not required for typical presentations.

Dermoscopy

Dermoscopy (a magnified view of the scalp using a handheld lens or digital device) adds confidence and detail to the diagnosis. Under dermoscopy, active alopecia areata typically shows yellow dots (empty follicular openings), black dots (broken hairs), and exclamation-mark hairs at the patch border. The presence of exclamation-mark hairs is considered a reliable sign of active disease.

Pull test

At the edge of an active patch, a gentle pull test will often yield hairs with ease - a sign that the follicle is releasing the shaft prematurely.

Biopsy and bloodwork

Scalp biopsy is reserved for atypical presentations where the diagnosis is uncertain. Bloodwork is not used to diagnose alopecia areata itself, but some dermatologists check thyroid function (TSH) and a few other blood levels because of the link with thyroid disease, although there are no firm guidelines on which tests are needed (Canadian Family Physician).

If you or a client notice a smooth, round bald patch - even a single small one - the right first step is a referral to a dermatologist or trichologist, not a product recommendation.

Current Treatment Options

Treatment for alopecia areata is stratified by severity - how much of the scalp (or body) is affected. No currently available treatment resolves the underlying autoimmune process, but several options can suppress the immune response and allow hair to regrow.

Limited patchy disease (under 50% scalp involvement)

Intralesional corticosteroid injections are the most common first-line treatment for adults with one or several patches. A fine needle delivers corticosteroid directly into the patch, suppressing local immune activity. When effective, new hair growth is typically visible within four to eight weeks. Injections are repeated every four to six weeks as needed. Topical corticosteroids are an alternative, particularly for children where injections are not practical, though generally considered less effective than intralesional delivery.

Minoxidil is sometimes used as an adjunct to other treatments to support hair regrowth, but it does not address the autoimmune process itself and is not considered a primary treatment for alopecia areata.

Extensive disease (50%+ scalp involvement)

Topical immunotherapy using agents such as diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE) is described as the best-documented treatment so far for severe and refractory alopecia areata (Singh and Lavanya, International Journal of Trichology, 2010). These agents are applied to the scalp to deliberately induce a mild allergic reaction, which appears to shift the immune response away from the follicle. Reported response rates with DPCP vary widely by disease severity, ranging from roughly 60 percent in severe patchy disease to 17 percent in alopecia totalis or universalis.

JAK inhibitors: the newest FDA-approved options

The most significant advance in alopecia areata treatment in decades has been the approval of oral JAK inhibitors - drugs that block the Janus kinase signaling pathways that activate the T cells responsible for follicle attack. Three are now FDA-approved for severe alopecia areata:

• Baricitinib (Olumiant) - Approved June 2022 for adults with severe alopecia areata; its current prescribing information (revised September 2026) also covers adolescents 12 and older. The first systemic treatment FDA-approved specifically for this condition. In clinical trials (BRAVE-AA1 and BRAVE-AA2), 32 to 35 percent of patients at the 4mg dose achieved 80 percent or more scalp hair coverage after 36 weeks.
• Ritlecitinib (Litfulo) - Approved June 2023 for adults and adolescents 12 and older with severe alopecia areata. At approval it was the first approved treatment for people under 18, and baricitinib (Olumiant) is now approved for ages 12 and older as well, according to its prescribing information.
• Deuruxolitinib (Leqselvi) - Approved July 2024 for adults 18 and older, the third oral JAK inhibitor approved for severe alopecia areata.

A note on all alopecia areata treatments: response varies widely between individuals, relapse after stopping treatment is common, and no treatment is appropriate for every person or every severity level. Treatment decisions should be made in consultation with a board-certified dermatologist.

What Scalp Care Can and Cannot Do

This is where it is important to be direct. Scalp care products - shampoos, conditioners, serums, oils, scalp treatments - do not treat alopecia areata. They cannot modulate the immune response, interrupt the autoimmune process, or stimulate hair growth in follicles under immune attack. Anyone who tells a person with alopecia areata that a topical product will grow their hair back is providing false hope.

What good scalp care can do is support the scalp environment while a person is pursuing appropriate medical treatment:

• Barrier protection - Gentle, non-irritating cleansing helps maintain a healthy scalp barrier, which matters especially when topical corticosteroids are being used alongside normal scalp routines.
• Sun protection for exposed patches - Areas of complete hair loss are exposed to UV radiation. Dermatologists often recommend covering patches with hats or applying SPF to exposed scalp areas.
• Comfort during treatment - Scalp sensitivity is common during active disease or treatment. Products free from harsh surfactants and fragrance can reduce baseline irritation.
• Psychological comfort - Hair loss from any cause has meaningful psychological effects. A consistent scalp care routine can provide a sense of agency during a condition that often feels outside a person's control.

For clients managing alopecia areata, the appropriate role of a salon professional or scalp care brand is to support their comfort and their scalp barrier health - and to encourage them to maintain their relationship with a dermatologist for the actual treatment decisions. See also: why hair loss happens for a broader overview of the clinical landscape.

Living With It: Regrowth Is Unpredictable

Alopecia areata is, by nature, unpredictable. That is one of the most difficult things about it - both for people living with the condition and for the professionals supporting them.

Spontaneous remission

In limited patchy cases, spontaneous regrowth without any treatment occurs in a meaningful portion of patients. Estimates vary widely: one review cites regrowth in roughly 40 to 70 percent of people with limited patchy disease (Canadian Family Physician), while pooled data from placebo-controlled trials shows more modest rates (Acta Dermato-Venereologica). For extensive disease, totalis, or universalis, spontaneous recovery is far less common.

What regrowth looks like

When hair does regrow, it often appears as fine, white, or lightly pigmented hair initially. This vellus-type regrowth can be alarming if someone is not prepared for it. Over the following weeks to months, the hair typically thickens and repigments. The return of normally pigmented, terminal hair is generally a good sign that the follicle has recovered and the immune attack has subsided.

Recurrence

Even after full regrowth, recurrence is common. Alopecia areata is a chronic condition with a relapsing-remitting course for many people. A single episode that resolved completely does not guarantee the condition will not return. The extent of hair loss at first presentation is closely tied to long-term course: regrowth is inversely related to how much hair is lost, and limited first episodes generally carry a better prognosis than extensive or early-onset disease (Canadian Family Physician).

Community and support

The National Alopecia Areata Foundation (NAAF) provides community resources, peer support networks, and updated treatment guidance for people living with the condition. Psychological support is a legitimate and important part of managing a condition that significantly affects appearance and, for many people, identity.